Regulatory News
March 23, 2018 / 12:53 PM / a year ago

BRIEF-EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca

1 Min Read

March 23 (Reuters) - EU Medicines Agency:

* RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY OVARIAN CANCER DRUG RUBRACA

* EU MEDICINES AGENCY SAYS RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR CLOVIS OVARIAN CANCER DRUG RUBRACA Source text - (bit.ly/2pBz519) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below